Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
RegulatoryAbbVie Launches Phase 2 Forehead Lines StudytodayMarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days agoBusiness & M&AAllergan Aesthetics Overhauls Loyalty ProgramtodayDevices & TechXERF Technology Enters Australian Market for Skin Tightening2 days agoBusiness & M&AEvolus Expands Estyme to Canada, Australia, New ZealandtodayMarketArm Fat Now Top Body Sculpting Concern in Singapore2 days agoDevices & TechSofwave Hits One Million Treatments MilestonetodayRegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days agoRegulatoryRevance Wins FDA Nod for Under-Eye InjectablesyesterdayMarketGLP-1 Pill Era Is Forcing Beauty Market ShiftyesterdayInjectablesAEON Releases Expanded ABP-450 Botox Biosimilar DatayesterdayDevices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday
Trade & Tariffs

Entity List

A Commerce Department blacklist barring U.S. firms from supplying named foreign companies without a license.

Also known as: BIS Entity List

What it is
The Entity List is a Commerce Department roster of foreign parties subject to license requirements for receiving U.S.-origin items. Being listed sharply restricts what American suppliers can sell to them. Licenses are often presumptively denied.
What it does
Adding a major foreign customer to the list can eliminate a revenue stream for U.S. suppliers overnight, while sometimes benefiting non-U.S. competitors. Investors map supplier exposure to newly listed entities. It is a precise, single-target catalyst.
The evidence
Placing large foreign technology firms on the Entity List has forced U.S. suppliers to halt shipments and disclose revenue impacts.
Best for
Chip and component suppliers exposed to listed customers; varies by disclosure.
Pairs well with
export-controls, sanctions, section-301
Use cautiously with
Temporary general licenses and workarounds can soften the blow; assuming an instant total cutoff overstates near-term impact.
Cautions
Exposure is often undisclosed at the customer level, so estimates carry uncertainty.
General information, not medical advice. Ingredient effects vary by formulation, concentration, and skin. Patch-test new actives and consult a qualified provider before starting prescription ingredients.

Know what's coming before your patients ask for it.

New actives, device launches, and the FDA calls that change what you can offer — distilled into a two-minute brief, twice a week. Inside MedSpa Pro.

Go Pro · $20/mo
Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
The twice-a-week intelligence brief Go Pro · $20/mo